Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CEO Christopher Richard Anzalone Sells 26,712 Shares of Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CEO Christopher Richard Anzalone sold 26,712 shares of the firm’s stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $21.24, for a total transaction of $567,362.88. Following the completion of the sale, the chief executive officer now owns 3,688,335 shares of the company’s stock, valued at approximately $78,340,235.40. The trade was a 0.72 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Arrowhead Pharmaceuticals Stock Performance

NASDAQ:ARWR opened at $19.45 on Friday. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 2.06. The company has a market capitalization of $2.42 billion, a P/E ratio of -3.87 and a beta of 0.91. The firm has a 50-day moving average price of $21.23 and a two-hundred day moving average price of $23.09. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $17.05 and a twelve month high of $39.83.

Institutional Trading of Arrowhead Pharmaceuticals

Several large investors have recently modified their holdings of the business. SG Americas Securities LLC lifted its stake in Arrowhead Pharmaceuticals by 27.4% in the 2nd quarter. SG Americas Securities LLC now owns 9,369 shares of the biotechnology company’s stock valued at $244,000 after buying an additional 2,014 shares in the last quarter. Fifth Third Bancorp raised its holdings in shares of Arrowhead Pharmaceuticals by 42.5% in the second quarter. Fifth Third Bancorp now owns 1,186 shares of the biotechnology company’s stock worth $31,000 after acquiring an additional 354 shares during the last quarter. EFG Asset Management North America Corp. lifted its position in shares of Arrowhead Pharmaceuticals by 86.8% in the second quarter. EFG Asset Management North America Corp. now owns 51,828 shares of the biotechnology company’s stock valued at $1,346,000 after acquiring an additional 24,083 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Arrowhead Pharmaceuticals by 2.9% during the second quarter. Bank of New York Mellon Corp now owns 1,085,069 shares of the biotechnology company’s stock valued at $28,201,000 after acquiring an additional 30,086 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in Arrowhead Pharmaceuticals by 20.7% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 28,739 shares of the biotechnology company’s stock worth $747,000 after purchasing an additional 4,927 shares in the last quarter. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have recently commented on the company. Piper Sandler reduced their price target on Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating for the company in a report on Wednesday, November 27th. Sanford C. Bernstein reduced their target price on Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating for the company in a report on Friday, November 29th. Chardan Capital reaffirmed a “buy” rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Thursday, December 12th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arrowhead Pharmaceuticals in a research note on Monday, September 9th. Finally, HC Wainwright reissued a “buy” rating and set a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Friday. One analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $42.70.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.